Previous close | 0.1000 |
Open | 0.1000 |
Bid | 0.0000 |
Ask | 0.7500 |
Strike | 12.50 |
Expiry date | 2023-12-15 |
Day's range | 0.1000 - 0.1000 |
Contract range | N/A |
Volume | |
Open interest | 519 |
With the business potentially at an important milestone, we thought we'd take a closer look at Esperion Therapeutics...
– A Prespecified, Exploratory Analysis of Participants Reports Those with Higher Baseline Inflammation More Likely to Experience a Major Cardiovascular Event (MACE), Cardiovascular Death, and All-Cause Mortality Compared to Those with the Lowest Inflammation – – 21.6% Reduction in Vascular Inflammatory Marker High Sensitivity C-reactive Protein (hsCRP) in Patients Taking Bempedoic Acid – – Results Simultaneously Published in Circulation – ANN ARBOR, Mich., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Esper
– Data from Randomized Control Trial Will Advance Evidence for Evaluation and Treatment of Heart Disease by Studying Actual Disease: Atherosclerosis – ANN ARBOR, Mich., Nov. 11, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced participation in the TRANSFORM trial at the American Heart Association’s (AHA) 2023 Scientific Sessions. TRANSFORM is a randomized control trial – sponsored by Cleerly – that aims to enroll 7,500 patients who have pre-diabetes, type 2 diabetes, or metabolic syndr